www.smh.com.au

News Store Help

Prima presents at ISCT annual meeting

Announced by: PRR
Announced on: 04/02/2013 10:43:57
          Words: 585
Status: Not market sensitive (N)
View original PDF
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au
ABN: 90 009 237 889


ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
4 February 2013
PRIMA BIOMED ANNOUNCES TWO ACCEPTED ABSTRACTS FOR PRESENTATION AT ISCT
ANNUAL MEETING

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
("Prima", "the Company") announces that two abstracts related to research and development
of CVacTM have been accepted by the International Society for Cellular Therapy (ISCT) for
presentation at its 19
th
annual meeting in Auckland, New Zealand from 22-25 April 2013.

The two poster presentations are;
"Qualification of an intracellular cytokine staining (ICS) assay to evaluate mucin 1-specific T
cell responses in ovarian cancer patients treated with CVacTM immunotherapy" by Dr.
Sharron Gargosky et al.; and
"Qualification of the COSTIM assay to determine potency and use in clinical trials" by Dr.
Michael Buchholtz et al.

Dr. Gargosky's poster will describe the use of intracellular cytokine staining (ICS) assays to
measure mucin 1-specific T cells in patient's peripheral blood mononuclear cells (PBMC). Dr.
Buchholtz's poster will describe the process of developing and qualifying the COSTIM assay to
assess the potency of a product like CVacTM.

Both posters will be presented during the Immunotherapy, Regenerative Medicine,
Translational Process Development and Gene Therapy session on Wednesday, 24 April 2013
from 5:00pm to 6:30pm.


ENDS


About Prima BioMed

Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-
therapeutic products for cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and to maximize value to
shareholders. Prima's lead product is CVacTM, an autologous dendritic cell product currently in
clinical trials for ovarian cancer patients who are in remission.


Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au
ABN: 90 009 237 889
For further information please contact:

USA Investor/Media:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061;

Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574;

Europe Investor/Media:
Mr. Axel Mühlhaus, edicto GmbH
+49 (0) 69 905505-52;
 
Back  Back to Search Results